Many ME experts are doing both. RECOVER is considering adding ME/CFS arms to its huge clinical trial platform. UCSF just added ME/CFS as a priority in their LIINC program.
SARS-CoV-2 therapeutics won’t work on both but immune cell based ones may given they haven’t been tested in either yet.
Both suggest a root cause of persistent viral antigen. Time will tell what works here.